Navigation Links
MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
Date:5/23/2012

LONDON, May 23, 2012 /PRNewswire/ -- A number of large pharmaceutical and biotech companies are keen to invest in life science research. Advances in genomic technologies and molecular biology segments will boost the microRNA (miRNA) research and tools market in the future. MicroRNA is set to unveil a new era in molecular diagnostics and in the development of effective therapeutics.

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), Analysis of MicroRNA Tools and Services Market in Europe, covers miRNA tools such as qRT-PCR, microarray and functional analysis and services including expression profiling and phenotypic screening.

The adoption of miRNA research in different fields is, in turn, widening the use of related miRNA tools across an ever-expanding spectrum of applications.

"MicroRNA profiling has already been adopted in cancer research, stem cell research, developmental biology and neuroscience," notes Frost & Sullivan Research Consultant Vinodh Jyotikumar. "This has caused many other fields to develop an interest in auditing their gene expression analyses or epigenetic research by profiling miRNAs."

Recently, more research and development has been promoted in finding the utility and role of miRNAs in the field of cardiovascular research, plant science, virology, endocrinology and genetic disease. As researchers discover new miRNAs and study functions, additional research fields may realise that miRNAs can play a role in their disciplines.

A key challenge in the market relates to the widespread availability of miRNA research tools, which has resulted in reduced opportunities for the services sector.

The surge in miRNA research caused many life sciences vendors to enter the miRNA research tools market over the past four years. There are nearly 20 competitors in the market offering miRNA microarrays, qRT-PCR and functional analysis tools. The broad availability and increased product options of commercial miRNA research tools allows researchers to obtain their preferred technology easily and conduct miRNA research without the use of services.

As competition intensifies, market participants will need to expand their product options and capabilities, while focusing on achieving differentiation.

"Service providers that do not offer in-house technologies must differentiate themselves by expanding tool options or adding capabilities," elaborates Jyotikumar. "Companies may opt to provide multiple microarrays from various vendors, develop their own tools or offer specialised products, such as multiplex panels aimed at specific diseases."

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at janique.morvan@frost.com.

Analysis of MicroRNA Tools and Services Market in Europe is part of the Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: European PCR Reagent Market for Research and Clinical Diagnostics and European Next Generation Sequencing Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Analysis of MicroRNA Tools and Services Market in Europe
M788-55

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.  
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360-degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.  

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:         Join our community

Subscribe:       Newsletter on "the next big thing" 

Register:        Gain access to visionary innovation

Contact:
Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
E: janique.morvan@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
2. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
3. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
4. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
5. Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA
6. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
7. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
8. Phalanx Biotech Group Launches microRNA Microarray - miRBase v17
9. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
10. Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes
11. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)...  Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... a majority ownership interest in Dental Cremer S.A., a ... Brazil . --> ... the dental distribution business of Cremer S.A. With 2015 ...
Breaking Medicine Technology:
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... Buffalo, NY (PRWEB) , ... February 05, 2016 ... ... regional partners and setting the stage for new clinical and scientific initiatives have ... one year after she was appointed President and CEO of the nation’s oldest ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of micro-needling services in their Napa Valley office. The technique utilizes the body’s ... Associates, Dr. Canales and Dr. Furnas, are part of only a select few ...
(Date:2/5/2016)... ... 2016 , ... After years as an active staff surgeon and having served ... Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at what ... as chief and began a second three-year term in January of 2016. , The ...
(Date:2/5/2016)... Illinois (PRWEB) , ... February 05, 2016 , ... ... and independent PROSHRED franchises from across the country gathered at the La Valencia ... recognize top performers. PROSHRED Chicago was named the year’s most outstanding franchise, ...
Breaking Medicine News(10 mins):